200799-19-5

Basic information

• Product Name: 2,6-DIMETHYL-4-FLUOROBENZYL BROMIDE
• Synonyms: 2,6-DIMETHYL-4-FLUOROBENZYL BROMIDE;2-(BroMoMethyl)-5-fluoro-1,3-diMethylbenzene
• CAS NO: 200799-19-5
• Molecular Formula: C₉H₁₀BrF
• Molecular Weight: 217.08
• Product Categories: Aromatics, Miscellaneous Reagents
• Mol File: 200799-19-5.mol

Chemical Properties

• Boiling Point: 244.9°Cat760mmHg
• Flash Point: 105°C
• Appearance: /
• Density: 1.394g/cm³
• Vapor Pressure: 0.046mmHg at 25°C
• Refractive Index: 1.536
• CAS DataBase Reference: 2,6-DIMETHYL-4-FLUOROBENZYL BROMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-DIMETHYL-4-FLUOROBENZYL BROMIDE(200799-19-5)
• EPA Substance Registry System: 2,6-DIMETHYL-4-FLUOROBENZYL BROMIDE(200799-19-5)

Safety Data

• Statements: 34-36/37/38
• Safety Statements: 26-36/37/39
• RIDADR: 1760
• Hazardous Substances Data: 200799-19-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,6-DIMETHYL-4-FLUOROBENZYL BROMIDE is used as a key intermediate in the synthesis of UDP-antagonists of P2Y14. These antagonists are important for the development of drugs targeting the P2Y14 receptor, which plays a crucial role in various physiological processes, including inflammation and pain perception. By modulating the activity of this receptor, the antagonists can potentially provide therapeutic benefits in treating conditions such as rheumatoid arthritis, inflammatory bowel disease, and neuropathic pain.

InChI:InChI=1/C9H10BrF/c1-6-3-8(11)4-7(2)9(6)5-10/h3-4H,5H2,1-2H3

Upstream product

• 50-00-0 formaldehyd 
• 461-97-2 3,5-dimethylfluorobenzene 

Downstream Products

• 1588424-29-6 7-chloro-1-ethyl-3-(4-fluoro-2,6-dimethylphenyl)-1,6-naphthyridin-2(1H)-one 
• 1588424-28-5 7-chloro-1-ethyl-3-(4-fluoro-2,6-dimethylphenyl)-1,6-naphthyridin-2(1H)-imine 
• 1175143-04-0 C₂₇H₂₇FN₄O 
• 945541-52-6 (4-fluoro-2,6-dimethyl-phenyl)-acetonitrile 
• 200799-10-6 4-(2,6-dimethyl-4-fluorobenzyloxy)-2-methylbenzimidazole 

Relevant articles and documents

COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION

The present disclosure relates generally to compounds and pharmaceutical compositions for the selective inhibition of histone lysine demethylase5 (KDM5), particularly KDM5B, and methods of their use in treating conditions and diseases associated with KDM5 activity.

NOVEL HETEROCYCLIC COMPOUNDS AS BET INHIBITORS

Provided are heterocyclic compounds of formula (I) as bromodomain and extraterminal (BET) inhibitors, pharmaceutical compositions comprising the compounds, their synthesis and their use for treating diseases and conditions wherein inhibition of one or more BET bromodomains provides a benefit.

Imidazo[1,2-a]pyridine derivatives, methods of preparing the same and use thereof

The present invention relates to an imidazo[1,2-a]pyridine derivative, and more specifically, to an imidazo[1,2-a]pyridine derivative having excellent gastric acid secretion inhibitory activity, a method of preparing the same, and a use thereof. The imidazo[1,2-a]pyridine derivative according to the present invention has gastric acid secretion inhibitory activity, and can be usefully applied for preventing or treating gastrointestinal inflammatory diseases or gastric-related diseases.(AA) Control group(BB) Example 6(CC) Example 7(DD) Embodiment 11COPYRIGHT KIPO 2017

MULTIPLE KINASE PATHWAY INHIBITORS

Kinase with inhibitory activity against kinases disposed in multiple signaling pathways and their therapeutic uses.

BENZYL-SUBSTITUTED BENZIMIDAZOLES

The present invention relates to benzimidazole derivatives of the formula (I), in which the phenyl moiety is substituted with lower alkyl in 2- and 6-position, which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be use

Compounds for inhibition of gastric acid secretion

The present invention relates to imidazo pyridine derivatives of the formula (I), in which the phenyl moiety is substituted with lower alkyl in 2- and 6-position, which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be